	US 11,919,929 B1
	Recombinant Fasciola hepatica fatty acid binding protein suppresses toll-like receptor stimulation in response to multiple bacterial ligands
Ana M. Espino, San Juan, PR (US); and Marcos J. Ramos-Benitez, San Juan, PR (US)
Assigned to UNIVERSITY OF PUERTO RICO, San Juan, PR (US)
Filed by UNIVERSITY OF PUERTO RICO, San Juan, PR (US)
Filed on Feb. 20, 2019, as Appl. No. 16/280,999.
Application 16/280,999 is a continuation in part of application No. 15/156,284, filed on May 16, 2016, granted, now 10,376,561, issued on Aug. 13, 2019.
Claims priority of provisional application 62/632,998, filed on Feb. 20, 2018.
Claims priority of provisional application 62/161,582, filed on May 14, 2015.
Int. Cl. C07K 14/435 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01); A61P 29/00 (2006.01)

CPC C07K 14/43559 (2013.01) [A61K 9/0019 (2013.01); A61P 29/00 (2018.01); A61K 38/00 (2013.01)]

10 Claims

1. A method of reducing TLR4-mediated inflammation in a mammal, the method comprising the steps of:

(a) obtaining recombinant Fasciola hepatica fatty acid binding protein (rFh15); and

(b) administering to the mammal an amount of rFh15 effective to down-regulate CD38 in spleen macrophages.